Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more

Bibliographic Details
Main Authors:	Zhi-Bin Wang, Dan Liu, Guang Lei, Zhao-Qian Liu, Nayiyuan Wu, Jing Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Pharmacology
Subjects:	ovarian cancer targeted medication immunomodulatory drug resistance PARP inhibitors anti-angiogenic drugs
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1222209/full

Similar Items

Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022-12-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine
by: Chao Mei, et al.
Published: (2023-03-01)

PARP inhibitors combined with radiotherapy: are we ready?
by: Chen Sun, et al.
Published: (2023-10-01)

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
by: Yaxin Liu, et al.
Published: (2023-09-01)

PARP Inhibitors in Breast and Ovarian Cancer
by: Samuel S. Y. Wang, et al.
Published: (2023-04-01)

Testing Doses and Treatment Timelines of Anti-Angiogenic Drug Bevacizumab Numerically as a Single-Agent for the Treatment of Ovarian Cancer
by: Dharma Raj Khatiwada, et al.
Published: (2023-01-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
by: Nicoletta Cordani, et al.
Published: (2023-07-01)

The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma
by: Yelan Guan, et al.
Published: (2023-01-01)

Tertiary Prevention of Ovarian Cancer After PARP Inhibitor Therapy
by: ZANG Rongyu
Published: (2023-02-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer
by: Lama Abujamous, et al.
Published: (2024-03-01)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
by: Michelle McMullen, et al.
Published: (2020-06-01)

Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
by: Olivia El Naggar, et al.
Published: (2022-05-01)

Anti-Angiogenic Activity of Drugs in Multiple Myeloma
by: Ilaria Saltarella, et al.
Published: (2023-03-01)

Effect of anti-angiogenic drugs along with chemotherapy in breast cancer treatment: review article
by: Najibeh Nasiri, et al.
Published: (2019-07-01)

Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022
by: Jiahua Liu, et al.
Published: (2023-05-01)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
by: Xiaoyu Fu, et al.
Published: (2024-01-01)

Corrigendum: Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022
by: Jiahua Liu, et al.
Published: (2023-05-01)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
by: Camilla Nero, et al.
Published: (2021-03-01)

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
by: Shona Nag, et al.
Published: (2022-07-01)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
by: Yuan Qiao, et al.
Published: (2022-10-01)

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer
by: Inken Flörkemeier, et al.
Published: (2022-09-01)

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
by: Anna Jo Bodurtha Smith, et al.
Published: (2024-04-01)

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
by: Jiajia Li, et al.
Published: (2023-01-01)

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
by: Yongsong Wu, et al.
Published: (2023-01-01)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
by: Brigida Anna Maiorano, et al.
Published: (2022-03-01)

Discovery of novel 2,3,4,5-tetrahydrospiro[benzo[c]azepine-1,1’-cyclohexan]-5-ol derivatives as PARP-1 inhibitors
by: Ling Yu, et al.
Published: (2023-10-01)

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
by: Chien-Hui Lau, et al.
Published: (2022-07-01)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
by: Michele Bartoletti, et al.
Published: (2020-05-01)

Fasting mimicking diet inhibits tumor-associated macrophage survival and pro-tumor function in hypoxia: implications for combination therapy with anti-angiogenic agent
by: Lei Wang, et al.
Published: (2023-10-01)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
by: Bin Tang, et al.
Published: (2023-04-01)

Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting
by: Zena Alizzi, et al.
Published: (2023-03-01)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
by: Michalis Liontos, et al.
Published: (2021-10-01)

The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems
by: Lisha Cai, et al.
Published: (2022-08-01)

Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients
by: Christina T. Grech, et al.
Published: (2022-09-01)

Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy
by: Cheng Qian, et al.
Published: (2023-12-01)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
by: Shane O’Brien, et al.
Published: (2023-08-01)

Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
by: Maritza P. Garrido, et al.
Published: (2021-12-01)